Evaxion Biotech EVAX is gearing as much as announce its quarterly earnings on Tuesday, 2025-05-27. This is a fast overview of what buyers ought to know earlier than the discharge.
Analysts are estimating that Evaxion Biotech will report an earnings per share (EPS) of $-0.25.
The market awaits Evaxion Biotech’s announcement, with hopes excessive for information of surpassing estimates and offering upbeat steering for the following quarter.
It is necessary for brand spanking new buyers to grasp that steering is usually a important driver of inventory costs.
Previous Earnings Efficiency
Within the earlier earnings launch, the corporate beat EPS by $0.08, resulting in a 1.81% enhance within the share worth the next buying and selling session.
This is a have a look at Evaxion Biotech’s previous efficiency and the ensuing worth change:
| Quarter | This autumn 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.15 | -3.1 | -3.9 | -5.6 |
| EPS Precise | -0.07 | -0.4 | -1.2 | 0.3 |
| Worth Change % | 2.0% | -3.0% | 10.0% | -6.0% |
Market Efficiency of Evaxion Biotech’s Inventory
Shares of Evaxion Biotech have been buying and selling at $1.87 as of Could 22. Over the past 52-week interval, shares are down 90.18%. Provided that these returns are typically destructive, long-term shareholders are seemingly slightly upset going into this earnings launch.
To trace all earnings releases for Evaxion Biotech go to their earnings calendar on our web site.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
